Aya Fukuma Ozaki

Title(s)Assistant Professor, Clinical Pharmacy Practice
SchoolSchool of Pharmacy and Pharmaceutical Sciences
Address101 Theory, Suite 100
Irvine CA 92697-3958
Phone(949) 824-3942
vCardDownload vCard

    Collapse Bibliographic 
    Collapse publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Machine learning approaches to predict early cardiac immune-related adverse events in patients receiving immune checkpoint inhibitors. Support Care Cancer. 2026 Jul 29; 34(8). Sayer M, Chang PD, Hamano H, Yamamoto R, Nagasaka M, Naqvi AA, Patel PM, Zamami Y, Ozaki AF. PMID: 42521802; PMCID: PMC13415296.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    2. Prescription patterns of sacubitril/valsartan among patients with hypertension in Japan. Front Cardiovasc Med. 2026; 13:1738988. Ozaki AF, Nomura H, Terada T, Kato ET, Naqvi AA, Nguyen JT, Kunitsu Y. PMID: 42539654; PMCID: PMC13423890.
      View in: PubMed   Mentions:
    3. Correction: Prevention and management of cardiovascular disease in adults with cancer: an International Cardio-Oncology Society (IC-OS) and Multinational Association of Supportive Care in Cancer (MASCC) clinical practice statement. Cardiooncology. 2026 Jul 10; 12(1). Dent S, Nadler MB, Blaes A, Iqbal A, Ayettey HNG, Alvarez-Cardona J, Chan A, Koh ES, Mascunano RC, George M, Aryeetey NA, Howden EJ, Kazuhiro S, Latif N, Ozaki AF, Semple CJ, Ramalingam S, Iyenger NM, Rugo HS, Koczwara B. PMID: 42432812; PMCID: PMC13352844.
      View in: PubMed   Mentions:
    4. Correction: Prevention and management of cardiovascular disease in adults with cancer: an International Cardio‑Oncology Society (IC‑OS) and Multinational Association of Supportive Care in Cancer (MASCC) clinical practice statement. Support Care Cancer. 2026 Jun 30; 34(7). Dent S, Nadler MB, Blaes A, Iqbal A, Ayettey HNG, Alvarez-Cardona J, Chan A, Koh ES, Cordoba Mascunano R, George M, Aryeetey NA, Howden EJ, Kazuhiro S, Latif N, Ozaki AF, Semple CJ, Ramalingam S, Iyenger NM, Rugo HS, Koczwara B. PMID: 42377594; PMCID: PMC13319156.
      View in: PubMed   Mentions:    Fields:    
    5. Prevention and management of cardiovascular disease in adults with cancer: an International Cardio-Oncology Society (IC-OS) and Multinational Association of Supportive Care in Cancer (MASCC) clinical practice statement. Cardiooncology. 2026 May 29; 12(1). Dent S, Nadler MB, Blaes A, Iqbal A, Ayettey HNG, Alvarez-Cardona J, Chan A, Koh ES, Mascunano RC, George M, Aryeetey NA, Howden EJ, Kazuhiro S, Latif N, Ozaki AF, Semple CJ, Ramalingam S, Iyenger NM, S Rugo H, Koczwara B. PMID: 42216106; PMCID: PMC13220357.
      View in: PubMed   Mentions: 1  
    6. Prevention and management of cardiovascular disease in adults with cancer: an International Cardio-Oncology Society (IC-OS) and Multinational Association of Supportive Care in Cancer (MASCC) clinical practice statement. Support Care Cancer. 2026 May 29; 34(6). Dent S, Nadler MB, Blaes A, Iqbal A, Ayettey HNG, Alvarez-Cardona J, Chan A, Koh ES, Mascunano RC, George M, Aryeetey NA, Howden EJ, Kazuhiro S, Latif N, Ozaki AF, Semple CJ, Ramalingam S, Iyenger NM, Rugo HS, Koczwara B. PMID: 42209784; PMCID: PMC13219080.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    7. Co-expression of PKCζ and ALDH1A3 Is Associated With Poor Chemotherapeutic Responses in Basal-like Breast Cancer. Cancer Genomics Proteomics. 2026 Mar-Apr; 23(2):322-341. Nagashima Y, Ogino M, Okiyama R, Chiwaki R, Ishii H, Nohata K, Nakahara A, Ozaki A, Kasai T, Tamori S, Ohno S, Sasaki K, Akimoto K. PMID: 41771575; PMCID: PMC12951394.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    8. Exploratory Analysis for Development Predictive Models of Immune Checkpoint Inhibitor-Induced Myocarditis Using a Nationwide Claims Database. Biol Pharm Bull. 2026; 49(1):66-73. Yamamoto R, Hamano H, Nakagomi K, Uchiyama M, Michihara A, Ozaki AF, Patel PM, Tanioka M, Zamami Y, Uehara T. PMID: 41526226.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    9. High p62 and ALDH1A3 Reduce the Effectiveness of Endocrine Therapy in Luminal B Breast Cancer. Cancer Diagn Progn. 2025 Nov-Dec; 5(6):677-697. Maemura Y, Ozaki A, Chiwaki R, Enomoto M, Tada Y, Nagashima Y, Ishii H, Nohata K, Kasai T, Okiyama R, Harada Y, Tamori S, Ohno S, Sasaki K, Akimoto K. PMID: 41179310; PMCID: PMC12577621.
      View in: PubMed   Mentions: 1  
    10. High Expression of PKCζ and ALDH1A3 Is Associated With Poor Prognosis in Luminal B Breast Cancer. Anticancer Res. 2025 Oct; 45(10):4357-4372. Nagashima Y, Sasaki K, Nohata K, Chiwaki R, Maemura Y, Kasai T, Ozaki A, Tamori S, Ohno S, Akimoto K. PMID: 41006005.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    11. An evaluation of racial and ethnic disparities in cardiovascular risks in patients who underwent percutaneous coronary intervention. Int J Cardiol. 2025 Dec 15; 441:133776. Cadiz CL, Au S, Shin S, Rasouli M, Naqvi A, Ozaki AF. PMID: 40812622.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    12. High Expression of PKCζ And CTNNBIP1 Is Associated With Poor Prognosis in Luminal B Breast Cancer. Cancer Genomics Proteomics. 2025 Jun 26; 22(4):538-556. Nagashima Y, Sasaki K, Chiwaki R, Ishii H, Nohata K, Maemura Y, Kasai T, Ozaki A, Tamori S, Ohno S, Akimoto K. PMID: 40571311; PMCID: PMC12216573.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    13. Balancing the Risk of Cardiotoxicity Outcomes in Treatment Selection for Multiple Myeloma: A Retrospective Multicenter Evaluation of Ixazomib, Lenalidomide, and Dexamethasone (IRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (KRd). EJHaem. 2025 Jun; 6(3):e70038. Lee BJ, Sayer M, Naqvi AA, Mai KT, Patel PM, Lee LX, Ozaki AF. PMID: 40297748; PMCID: PMC12036692.
      View in: PubMed   Mentions: 2  
    14. Time dependent predictors of cardiac inflammatory adverse events in cancer patients receiving immune checkpoint inhibitors. Cardiooncology. 2025 Apr 28; 11(1):40. Sayer M, Hamano H, Nagasaka M, Lee BJ, Doh J, Patel PM, Zamami Y, Ozaki AF. PMID: 40296103; PMCID: PMC12036232.
      View in: PubMed   Mentions: 1  
    15. Incidence and survival outcomes of myocarditis and pericardial diseases associated with immune checkpoint inhibitor therapy. Cardiooncology. 2025 Mar 05; 11(1):26. Ozaki AF, Sayer M, Hamano H, Nagasaka M, Lee BJ, Doh J, Naqvi A, Nowrouzi N, Zamami Y, Patel PM. PMID: 40045435; PMCID: PMC11881249.
      View in: PubMed   Mentions: 5  
    16. Racial Disparities in Mood Stabilizer Prescribing in Mania in Nonpsychotic, Hospitalized Patients With Bipolar I Disorder. J Clin Psychiatry. 2025 02 03; 86(1). Khorassani F, Entsuah-Boateng N, Sayer M, Ozaki A. PMID: 39928844.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    17. Sex-based disparities with cost-related medication adherence issues in patients with hypertension, ischemic heart disease, and heart failure. J Am Med Inform Assoc. 2024 12 01; 31(12):2924-2931. Agapito I, Hoang T, Sayer M, Naqvi A, Patel PM, Ozaki AF. PMID: 39083847; PMCID: PMC11631144.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    18. Co‑expression of SLC20A1 and ALDH1A3 is associated with poor prognosis, and SLC20A1 is required for the survival of ALDH1‑positive pancreatic cancer stem cells. Oncol Lett. 2024 Sep; 28(3):426. Matsuoka I, Kasai T, Onaga C, Ozaki A, Motomura H, Maemura Y, Tada Y, Mori H, Hara Y, Xiong Y, Sato K, Tamori S, Sasaki K, Ohno S, Akimoto K. PMID: 39021737; PMCID: PMC11253103.
      View in: PubMed   Mentions: 2  
    19. Comparing Measures of Adherence and Persistence to P2Y12 Inhibitors in Acute Coronary Syndromes. Am J Cardiol. 2024 09 01; 226:134-136. Moon J, Ozaki AF, Chong A, Sud M, Fang J, Austin PC, Ko DT, Jackevicius CA. PMID: 38697453.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    20. Luminal B Breast Cancer Coexpressing p62 and ALDH1A3 Is Less Susceptible to Radiotherapy. Anticancer Res. 2024 Jan; 44(1):37-47. Ozaki A, Matsuda A, Maemura Y, Tada Y, Kasai T, Nagashima Y, Onaga C, Hara Y, Kitabatake K, Tsukimoto M, Tamori S, Sasaki K, Ohno S, Akimoto K. PMID: 38160009.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    21. Trajectories of P2Y12 inhibitor adherence in patients with acute coronary syndromes. Pharmacoepidemiol Drug Saf. 2024 01; 33(1):e5704. Moon J, Ozaki AF, Chong A, Sud M, Fang J, Austin PC, Ko DT, Jackevicius CA. PMID: 37771242.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    22. High SLC20A1 Expression Indicates Poor Prognosis in Prostate Cancer. Cancer Diagn Progn. 2023 Jul-Aug; 3(4):439-448. Okamoto T, Onaga C, Matsuoka I, Ozaki A, Matsuda C, Kasai T, Xiong Y, Harada Y, Sato T, Nakano Y, Mano Y, Miyazaki S, Ishiguro H, Sato K, Tamori S, Sasaki K, Ohno S, Akimoto K. PMID: 37405223; PMCID: PMC10316049.
      View in: PubMed   Mentions: 3  
    23. Prescribing patterns and factors associated with sodium-glucose cotransporter-2 inhibitor prescribing in patients with diabetes mellitus and atherosclerotic cardiovascular disease. CMAJ Open. 2023 May-Jun; 11(3):E494-E503. Ozaki AF, Ko DT, Chong A, Fang J, Atzema CL, Austin PC, Stukel TA, Tu K, Udell JA, Naimark D, Booth GL, Jackevicius CA. PMID: 37311594; PMCID: PMC10270657.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    24. Association between immune checkpoint inhibitor-induced myocarditis and concomitant use of thiazide diuretics. Int J Cancer. 2023 10 15; 153(8):1472-1476. Mitsuboshi S, Hamano H, Niimura T, Ozaki AF, Patel PM, Lin TJ, Tanaka Y, Kimura I, Iwata N, Shiromizu S, Chuma M, Koyama T, Yamanishi Y, Kanda Y, Ishizawa K, Zamami Y. PMID: 37306521.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    25. High expression of PKCλ and ALDH1A3 indicates a poor prognosis, and PKCλ is required for the asymmetric cell division of ALDH1A3-positive cancer stem cells in PDAC. Biochem Biophys Res Commun. 2023 08 20; 669:85-94. Kasai T, Tamori S, Takasaki Y, Matsuoka I, Ozaki A, Matsuda C, Harada Y, Sasaki K, Ohno S, Akimoto K. PMID: 37267864.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    26. High Expression of CD58 and ALDH1A3 Predicts a Poor Prognosis in Basal-like Breast Cancer. Anticancer Res. 2022 Nov; 42(11):5223-5232. Xiong Y, Motomura H, Tamori S, Ozaki A, Onaga C, Hara Y, Sato K, Tahata K, Harada Y, Sasaki K, Zheng YW, Ohno S, Akimoto K. PMID: 36288878.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    27. High SLC20A1 Expression Is Associated With Poor Prognosis for Radiotherapy of Estrogen Receptor-positive Breast Cancer. Cancer Diagn Progn. 2022 Jul-Aug; 2(4):429-442. Onaga C, Tamori S, Matsuoka I, Ozaki A, Motomura H, Nagashima Y, Sato T, Sato K, Tahata K, Xiong Y, Nakano Y, Mano Y, Miyazaki S, Sasaki K, Ohno S, Akimoto K. PMID: 35813014; PMCID: PMC9254097.
      View in: PubMed   Mentions: 4  
    28. High Expression of p62 and ALDH1A3 Is Associated With Poor Prognosis in Luminal B Breast Cancer. Anticancer Res. 2022 Jul; 42(7):3299-3312. Ozaki A, Motomura H, Tamori S, Onaga C, Nagashima Y, Kotori M, Matsuda C, Matsuda A, Mochizuki N, Sato T, Hara Y, Sato K, Miyagi Y, Nagashima Y, Hanawa T, Harada Y, Xiong Y, Sasaki K, Ohno S, Akimoto K. PMID: 35790283.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    29. Hospital-Level Variation in Ticagrelor Use in Patients With Acute Coronary Syndrome. J Am Heart Assoc. 2022 07 05; 11(13):e024835. Ozaki AF, Jackevicius CA, Chong A, Sud M, Fang J, Austin PC, Ko DT. PMID: 35766263; PMCID: PMC9333376.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    30. High expression of SLC20A1 is less effective for endocrine therapy and predicts late recurrence in ER-positive breast cancer. PLoS One. 2022; 17(5):e0268799. Onaga C, Tamori S, Matsuoka I, Ozaki A, Motomura H, Nagashima Y, Sato T, Sato K, Xiong Y, Sasaki K, Ohno S, Akimoto K. PMID: 35605014; PMCID: PMC9126382.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    31. Health Disparities in Pharmacy Practice Within the Community: Let's Brainstorm for Solutions. Front Public Health. 2022; 10:847696. Hurley-Kim K, Unonu J, Wisseh C, Cadiz C, Knox E, Ozaki AF, Chan A. PMID: 35462836; PMCID: PMC9024039.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    32. GLO 1 and PKCλ Regulate ALDH1-positive Breast Cancer Stem Cell Survival. Anticancer Res. 2021 Dec; 41(12):5959-5971. Motomura H, Tamori S, Yatani MA, Namiki A, Onaga C, Ozaki A, Takasawa R, Mano Y, Sato T, Hara Y, Sato K, Xiong Y, Harada Y, Hanawa T, Tanuma SI, Sasaki K, Ohno S, Akimoto K. PMID: 34848450.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    33. Prior Authorization, Copayments, and Utilization of Sacubitril/Valsartan in Medicare and Commercial Plans in Patients With Heart Failure With Reduced Ejection Fraction. Circ Cardiovasc Qual Outcomes. 2021 09; 14(9):e007665. Ozaki AF, Krumholz HM, Mody FV, Tran TT, Le QT, Yokota M, Jackevicius CA. PMID: 34465124.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    34. National Trends in the Use of Sacubitril/Valsartan. J Card Fail. 2021 08; 27(8):839-847. Ozaki AF, Krumholz HM, Mody FV, Jackevicius CA. PMID: 34364661.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    35. Glyoxalase 1 and protein kinase Cλ as potential therapeutic targets for late-stage breast cancer. Oncol Lett. 2021 Jul; 22(1):547. Motomura H, Ozaki A, Tamori S, Onaga C, Nozaki Y, Waki Y, Takasawa R, Yoshizawa K, Mano Y, Sato T, Sasaki K, Ishiguro H, Miyagi Y, Nagashima Y, Yamamoto K, Sato K, Hanawa T, Tanuma SI, Ohno S, Akimoto K. PMID: 34093768; PMCID: PMC8170180.
      View in: PubMed   Mentions: 5  
    36. High SLC20A1 Expression Is Associated With Poor Prognoses in Claudin-low and Basal-like Breast Cancers. Anticancer Res. 2021 Jan; 41(1):43-54. Onaga C, Tamori S, Motomura H, Ozaki A, Matsuda C, Matsuoka I, Fujita T, Nozaki Y, Hara Y, Kawano Y, Harada Y, Sato T, Mano Y, Sato K, Akimoto K. PMID: 33419798.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    37. High PKCλ expression is required for ALDH1-positive cancer stem cell function and indicates a poor clinical outcome in late-stage breast cancer patients. PLoS One. 2020; 15(7):e0235747. Nozaki Y, Motomura H, Tamori S, Kimura Y, Onaga C, Kanai S, Ishihara Y, Ozaki A, Hara Y, Harada Y, Mano Y, Sato T, Sato K, Sasaki K, Ishiguro H, Ohno S, Akimoto K. PMID: 32658903; PMCID: PMC7357771.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    38. Real-World Adherence and Persistence to Direct Oral Anticoagulants in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis. Circ Cardiovasc Qual Outcomes. 2020 03; 13(3):e005969. Ozaki AF, Choi AS, Le QT, Ko DT, Han JK, Park SS, Jackevicius CA. PMID: 32148102.
      View in: PubMed   Mentions: 109     Fields:    Translation:Humans
    39. Population Impact of Generic Valsartan Recall. Circulation. 2020 02 04; 141(5):411-413. Jackevicius CA, Krumholz HM, Chong A, Koh M, Ozaki AF, Austin PC, Udell JA, Ko DT. PMID: 31707798.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    40. Cross-cultural Comparison of Pharmacy Students' Attitudes, Knowledge, Practice, and Barriers Regarding Evidence-based Medicine. Am J Pharm Educ. 2019 06; 83(5):6710. Ozaki AF, Nakagawa S, Jackevicius CA. PMID: 31333249; PMCID: PMC6630851.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    Aya's Networks
    Concepts (126)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (12)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCI Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-40-gb10dcd06 on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California